Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.80 +4.1%	$17.91	$13.50 ▼ $25.67	$4.08B	0.38	3.44 million shs	2.34 million shs
AVDL Avadel Pharmaceuticals	$15.24 +2.8%	$10.89	$6.38 ▼ $16.66	$1.44B	1.47	1.20 million shs	1.55 million shs
IBB iShares Biotechnology ETF	$139.84 +0.8%	$131.73	$107.43 ▼ $150.57	$5.68B	0.75	1.56 million shs	1.31 million shs
SANA Sana Biotechnology	$3.58 -0.6%	$3.64	$1.26 ▼ $7.30	$856.10M	1.9	6.06 million shs	3.67 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+4.09%	+4.77%	+3.49%	-12.83%	-0.22%
AVDL Avadel Pharmaceuticals	+2.83%	+11.32%	+37.67%	+66.92%	-6.39%
IBB iShares Biotechnology ETF	+0.78%	+0.78%	+3.27%	+15.33%	-5.61%
SANA Sana Biotechnology	-0.56%	+7.51%	-30.35%	+79.90%	-32.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.3907 of 5 stars	3.7	3.0	0.0	0.0	3.7	2.5	3.1
AVDL Avadel Pharmaceuticals	2.7256 of 5 stars	3.6	3.0	0.0	0.0	2.0	1.7	0.6
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	2.9804 of 5 stars	3.5	3.0	0.0	0.0	1.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	55.43% Upside
AVDL Avadel Pharmaceuticals	3.14	Buy	$19.67	29.05% Upside
IBB iShares Biotechnology ETF	2.65	Moderate Buy	$139.84	N/A
SANA Sana Biotechnology	3.00	Buy	$8.00	123.46% Upside

Current Analyst Ratings Breakdown

Latest AVDL, IBB, SANA, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
7/18/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$22.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.96	$0.56 per share	31.59	$1.67 per share	10.66
AVDL Avadel Pharmaceuticals	$169.12M	8.75	N/A	N/A	$0.93 per share	16.39
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.86	20.70	25.80	N/A	44.06%	41.01%	28.47%	11/6/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	254.00	N/A	-1.32%	-3.73%	-1.73%	11/11/2025 (Estimated)
IBB iShares Biotechnology ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	-$266.76M	-$1.06	N/A	N/A	N/A	N/A	-91.96%	-43.07%	N/A

Latest AVDL, IBB, SANA, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	-$0.16	+$0.04	-$0.39	N/A	N/A
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBB iShares Biotechnology ETF	$0.38	0.27%	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.21	5.33	2.78
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
IBB iShares Biotechnology ETF	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	2.47	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AVDL Avadel Pharmaceuticals	69.19%
IBB iShares Biotechnology ETF	62.45%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AVDL Avadel Pharmaceuticals	5.20%
IBB iShares Biotechnology ETF	N/A
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.63 million	230.28 million	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
IBB iShares Biotechnology ETF	N/A	40.90 million	N/A	Optionable
SANA Sana Biotechnology	380	237.81 million	166.23 million	Optionable

AVDL, IBB, SANA, and ADMA Headlines

Recent News About These Companies

Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect

August 21 at 12:59 PM | msn.com

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 21 at 7:59 AM | uk.finance.yahoo.com

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase ...

August 21 at 2:58 AM | bakersfield.comB

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

August 20 at 4:55 PM | tmcnet.com

Sana Biotechnology, Inc. Completes Sale of 3,358,208 Shares, Generating Approximately $86.3 Million in Gross Proceeds

August 20 at 4:51 PM | quiverquant.comQ

HC Wainwright Issues Optimistic Forecast for SANA Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Forecast for Sana Biotechnology Raised by Analyst

August 16, 2025 | americanbankingnews.com

Sana Biotechnology drops Washington plant build-out, pivots to CDMOs instead

August 14, 2025 | fiercepharma.comF

Sana Biotechnology Reports Non-Cash Impairment Losses

August 14, 2025 | theglobeandmail.com

Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00

August 14, 2025 | americanbankingnews.com

Sana Biotech Bails on Factory in Old AT&T Call Center

August 12, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.04 EPS

August 12, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by Brokerages

August 12, 2025 | marketbeat.com

Sana: Q2 Earnings Snapshot

August 11, 2025 | sfgate.com

Sana suspends build-out of Bothell manufacturing facility

August 11, 2025 | bizjournals.com

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

August 11, 2025 | manilatimes.netM

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

August 8, 2025 | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down - Here's What Happened

August 8, 2025 | marketbeat.com

Seattle biotech firm Sana Biotechnology raising $75 million through public offering

August 8, 2025 | bizjournals.com

Sana Biotechnology stock tumbles after pricing public offering

August 7, 2025 | investing.com

Sana Biotechnology 20.9M share Spot Secondary priced at $3.35

August 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVDL, IBB, SANA, and ADMA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.80 +0.70 (+4.09%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.48 -0.32 (-1.77%)

As of 08/22/2025 07:13 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Avadel Pharmaceuticals NASDAQ:AVDL

$15.24 +0.42 (+2.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.26 +0.02 (+0.12%)

As of 08/22/2025 07:57 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

iShares Biotechnology ETF NASDAQ:IBB

$139.84 +1.08 (+0.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$140.01 +0.17 (+0.13%)

As of 08/22/2025 07:50 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Sana Biotechnology NASDAQ:SANA

$3.58 -0.02 (-0.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.62 +0.04 (+1.12%)

As of 08/22/2025 07:53 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time